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Abstract
Spinal cord injury leads to immense disability and loss of quality of life in human with no satisfactory clinical cure.
Cell-based or cell-related therapies have emerged as promising therapeutic potentials both in regeneration of
spinal cord and mitigation of neuropathic pain due to spinal cord injury. This article reviews the various options
and their latest developments with an update on their therapeutic potentials and clinical trialing.
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Spinal cord injury-demography and economic
impact
Causes of spinal cord injury (SCI) include falls, motor
vehicle accidents, community violence, sports injury and
work-related injuries. Annual incidence rate of SCI
ranges from 15 to 40 per million [1] with an average
age of onset at under 30. There is male sex predomi-
nance over female of up to 5:1, with cervical and thor-
acic regions being the commonest region of trauma
[2-5]. Depending on the severity and level(s) of lesion,
spinal cord injury leads to a combination of loss of sen-
sory, motor and autonomic functions, translating to
clinical scenarios of paraplegia, tetraplegia, aphagia,
incontinence and neuropathic pain. This plethora of
sequelae leads to catastrophic loss of quality of life of
these young and otherwise healthy patients. Economic-
ally it also translates to immense economic costs due to
loss of work productivity and the demand of life-long
supportive care. It has been estimated that annual costs
of health care (including hospitalisation and rehabilita-
tion) for an average patient with spinal cord injury
range from US$21,450 in Veterans Health Facilities [6]
to US$88,585 in a community base setting [7].
Neuropathic pain after spinal cord injury
About 65-85% of patients will suffer from pain after
spinal cord injury and amongst them, 1/3 will have
severe pain [8]. Those who experience pain for longer
than 6 months are likely to continue for the next 3 to 5
years [9], with a propensity to worsen over time with
other associated symptoms like fatigue, weakness and
memory loss [10]. The type of pain experienced after
spinal cord injury can be classified as neuropathic, mus-
culoskeletal, visceral and others [11]. In a longitudinal
sample of 100 patients followed up to 26 weeks after
traumatic spinal cord injury, 40% of them reported mus-
culoskeletal pain, 36% reported neuropathic pain at the
level of lesion and 16% reported neuropathic pain below
level of lesion [12]. Neuropathic pain is more common
with incomplete lesions of the cord and is more often
associated with cervical as compared to other levels of
injury [12]. Like other types of neuropathic pain, pain
due to spinal cord injury remains as a major challenge
in pain management and so far the commonest therapy
is with opioids, albeit a 32% long term efficacy [13].
Cellular and molecular basis for neuropathic pain due to
spinal cord injury
A typical non-transection injury of the spinal cord
results in various degrees of contusion and compression,
causing mechanical disruption of microvascular struc-
tures resulting in hemorrhages, intravascular thrombosis
and vasospasm. This subsequently leads to local hypo-
perfusion, hypoxia and ischemic damage. Paradoxically,
a period of reperfusion of the ischemic tissue occurs
when vasospastic blood vessels relax, and this produces
free-radicals, notably peroxynitrite (ONOO
-), which pro-
gressively oxidize fatty acids in the cellular membranes
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membrane depolarisation and massive release of gluta-
mate from the injured axons, which subsequently over-
stimulates post-synaptic N-Methyl-D-aspartic acid
(NMDA) and a-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptors. As a result, cytoplas-
mic calcium inside the injured axons rises abruptly due
to influx from extracellular compartment and also
release from intracellular stores [14], triggering off a cas-
cade of calcium-dependent processes like activation of
lytic enzymes (calpains, phospholipase A2 and lipoxy-
genase), disruption of mitochondrial function and even
more free radicals generation (nitric oxide and peroxyni-
trite)[15], culminating in apoptosis and final death of the
axons. Excessive stimulation of NMDA/AMPA/kainite
receptors by glutamate also leads to a similar influx of
sodium ions into the intracellular compartment of the
axons, causing repolarisation failure and loss of axonal
function. Outside the injured axons, an inflammatory
cascade commences with invasion of neutrophils and
monocytes/macrophages which secret an array of
immuno-active mediators like cytokines (TNF-a,I L - 1 b
and IL-6), chemokines (CX3CL1 and CCL2) and neuro-
trophic factors (NGF and BDNF) which often contribute
to further inflammatory damage and pave the way for
neuropathic pain [16,17]. A summary of events which
happen after a spinal cord injury can be found in a
schematic flowchart in Figure 1. In recent years, signifi-
cant progress has been made in profiling the intricate
roles of these neuroinflammatory mediators and the
astroglial system in the pathogenesis of neuropathic
pain, and the topic has been extensively reviewed else-
where [18-21]. Details are beyond the scope of this
paper but worth noting is the latest concept of neuro-
pathic pain as a neuro-immune process with its severity
and chronicity determined by the net balance of concur-
rent pro-inflammatory (neurodegenerative) and anti-
inflammatory (neuroprotective) mechanisms [22].
Cell-based strategies for treating neuropathic
pain associated with spinal cord injury
Using primary adrenal medullary/chromaffin tissue or
cells
Descending tracts from the periaqueductal gray (PAG),
locus coeruleus, parabrachial nucleus, nucleus raphe
magnus, reticular formation, anterior pretectal nucleus,
thalamus and cerebral cortex are known to modulate
afferent nociceptive signals [23] at the spinal cord. This
is thought to mediate via an array of neurotransmitters
like brain-derived neurotrophic factors (BDNF), 5-
hydroxytrytamine (5-HT), noradrenaline, g-aminobutyric
acid (GABA), b-endorphins, enkephalins and galanin.
Since initial discovery of the colour reaction of the adre-
nal medulla to chromate salt in 1865 by Henle [24], the
term chromaffin cells refer to those that contain gran-
ules or vesicles which retain the chromium particles
upon chromaffin reaction. It was not until 1953 that
Hillarp et al. [25] and Blaschko et al. [26] independently
reported the findings of catecholamines in the granular
portion of abstract of bovine adrenal medullae. Subse-
quent work in the 1980’s revealed a collection of antino-
ciceptive neuropeptides and neurotrophins in these
chromaffin cells [27-29] which in theory, can be utilised
on their own or with catecholamines [30,31] in a mini-
pump logic for analgesic purposes. This cradled the pio-
neering work of Sagen et al. in 1986 who implanted
bovine chromaffin cells into the subarachnoid space of
lumbar spine of rats and found significant analgesia
which was dose-related to the amount of chromaffin
cells [32]. They obtained similar findings with allogeneic
transplants of adrenal medullary tissue [33], document-
ing significant increase of met-enkephalin-like immu-
noreactivity in the spinal cord cerebral spinal fluid
(CSF)[34] and prolongation of analgesia with the use of
intrathecal enkephalinase [35], substantiating the role of
opioid peptides in the analgesic mechanisms. Using
similar adrenal medullary allografts transplanted into
the subarachnoid space of rat spinal cord, they demon-
strated reduction of chronic pain in rats modeled for
arthritis [36] and peripheral neuropathy [37]. These pro-
mising data propelled the use of cadaveric adrenal
medullary transplants into subarachnoid space of five
palliative patients with intractable cancer pain [38]
(Table 1), amongst them there was 80% response rate
with significant reduction of pain and demand for
opioids when they were followed up to 1 year. Two
other clinical studies from France using adrenal medul-
lary transplants, one as a pilot with two patients having
chronic pain [39](Table 1), the other a Phase II study
with 15 patients diagnosed with intractable cancer pain
[40], reported similar clinical improvement plus increase
in CSF met-enkephalin levels. Albeit such promising
results, the use of adrenal medullary tissues carries three
limitations: (i) the minimal effective dose is still unclear
and the clinical response did not seem to be dose-
dependent; (ii) the time limit of the donor medullary tis-
sue to maintain its viability and antinociceptive potency
is uncertain [41]; (iii) donor shortage in clinical situa-
tion. To circumvent these difficulties, isolated bovine
chromaffin cells encapsulated by semipermeable poly-
mer membranes were successfully employed in sheep
recipients as a functional xenogeneic transplant with a
dose-related response [42]. This led to the development
of a prototype implant which was pilot-tested in seven
patients with severe non-cancer type of chronic pain
[43](Table 1), with data showing acceptable levels of
safety and device retrievability without the need of
immunosuppression.
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Details of immortalising cell lines prepared under
laboratory conditions are beyond the scope of this
paper. Suffice to say in the research of neuropathic pain,
Eaton et al. [62,63] made significant contribution in
immortalising two main cell lines which helped advance
the study of cellular therapy for pain. One of them is a
neural cell line RN33B, derived from E13 brainstem
raphe and immortalised with SV40 temperature-sensi-
tive allele of large T antigen (tsTag), which are then
conditioned to proliferate at 33°C and stop proliferation
at 39°C. RN33B can further be transfected with cDNA
either for synthesizing galanin [64], BDNF [65] or
GABA [62], either of which when transplanted in the
Figure 1 A simplified flowchart of pathological events after spinal cord injury leading to neuronal death, glial scar and neuropathic
pain.
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chronic constricting injury (CCI), demonstrated signifi-
cant reduction of neuropathic pain [62,64,65]. The sec-
ond cell line is bovine chromaffin cell line, where the
immortalised cells possess immuno-reactivities for met-
enkephalin, galanin GABA and 5-HT without further
gene transfection with minimal in vivo tumorigenicity
[63]. Despite the theoretical advantage of its unlimited
supply, these immortalised cell lines still carry oncogenic
potential and hence none of them has yet been
approved for clinical trial as a cellular therapy for spinal
cord injury without demonstrating a fool-proof reassur-
ance of dis-immortalisation. Also, there is as yet a reli-
able method of controlling the immortalised cells to
deliver the specific dose of neurotrophins for the desired
effect on neuropathic pain. That is especially relevant
when the secreted neurotrophins produce antagonistic
effects on pain at different concentrations: an excellent
example will be BDNF, where Miki et al. [44](Table 1)
demonstrated that systemic infusion of BDNF to rats
with ligated spinal nerves relieved mechanical neuro-
pathic pain at a lower concentration of 1 μg/h and,
Table 1 Synopsis of clinical studies using cellular therapies for chronic pain
Modality Methods Outcome References
Primary adrenal
medullary/
chromaffin tissue
Cadaveric adrenal medullary transplants into 5 subjects
with intractable cancer pain
80% response rate with reduced demand for opioid
analgesia
[38]
Allograft to lumbar in 2 subjects with chronic cancer pain Clinical improvement with increase in CSF Met-
enkephalin levels
[39]
Encapsulated bovine chromaffin cells implanted as a
device in subarachnoid space of 7 subjects with chronic
pain
Reduction of morphine requirement from 30-100%
within a period of 41-176 days post-implantation
[43]
Phase II trial with allograft to CSF space in 15 subjects
with cancer pain
Reduction of intra-thecal morphine dosage and
increase in CSF Met-enkephalin levels
[44]
Bone marrow-
MSC
Bone-marrow MSC co-cultured with autoimmune T-cells
given to 2 human subjects with chronic SCI
Recovery of motor and sensory functions up to 8
spinal cord levels within 6 months
[45]
Open label case-control study with 64 subjects (44 as trial
and 20 as control) using monthly intrathecal autologous
MSC transplant for 6 months
No significant differences found in terms of ASIA score,
55.8% of treated subjects developed neuropathic pain
[46]
Three cycles of allogeneic MSC treated CD34 cells given
over 14 months to a subject with incomplete SCI
Reduction of neuropathic pain by 70% and resumption
of motor and sexual activities
[47]
Bone marrow
transplant
Unmanipulated autologous bone marrow transplant to 20
subjects with complete SCI
Regime generally safe and feasible [48]
Phase I/II open label trial with 35 subjects having
complete SCI receiving autologous bone marrow with
GM-CSF
Clinical improvement in 30.4% of subjects with no
complication of tumour or neuropathic pain formation
[49]
Uncontrolled series in Ecuador with 52 subjects with SCI
given bone marrow stem cells
Clinical improvements described [50]
Phase I/II study with 297 patients with SCI receiving single
unmanipulated autologous bone marrow cells
Regime relatively safe with improvement in motor/
sensory functions in 1/3 subjects
[51]
Clinical pilot with 30 subjects with SCI receiving single
dose of ex-vivo expanded bone marrow transplant
Clinical improvement in subjects with < 6 months
injury, not sure if effects due to spontaneous recovery
[52]
Olfactory
ensheathing cells
(OEC)
Phase I/IIa study with 6 subjects with thoracic paraplegia
receiving autologous OEC and followed up at 1 yr and 3
yrs
1 out of 6 subjects had mild clinical improvement [53,54]
Uncontrolled trial with 16 subjects receiving heterologous
OEC from aborted foetuses
No improvement mentioned [55]
Pilot study with seven subjects (ASIA class A) having
olfactory mucosa autografts (OMA) into spinal cord
lesions, later escalated to a prospective study with 20
subjects
Feasible and safe procedure with improvement with
ASIA scores, bladder sensations and sphincter
functions, with additional radiological improvements in
the prospective study
[56,57]
Pilot study with 5 subjects with chronic SCI receiving
OMA
No significant improvement, development of syrinx in
one subject and myelomalacia in other 4
[58]
Schwann cells Pilot study with 4 subjects receiving autologous transplant
from sural nerve cultures
Overall no adverse effects with improvement in only
one subject
[59]
Anti-TNF-a One report of current usage of etanercept in one subject
with accident of T7 cord transection
Significant reduction of inflammation and motor
improvement
[60]
Anti-Nogo-A Phase I study with anti-Nogo-A given to > 50 subjects
within 14 days of SCI
Still under evaluation [61]
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a higher dose of 20 μg/h.
Using other engineered cell lines
Xu et al. [66] transfected and immortalised astrocytes
with cDNA carrying the human preproenkephalin gene
(hPPE) which was combined with the tetracycline-con-
trolled (Tet-on) expression system, and these astrocytes
were implanted into the subarachnoid space of rats with
CCI. The group documented significant rise of spinal
enkephalin in these rats as regulated by doxycycline
administration in a dose-dependent fashion, with allevia-
tion of thermal and mechanical hyperalgesia. In a recent
experiment [67], the same group applied similar proto-
cols using preprogalanin cDNA (without tetracycline-
controlled expression system) and found increased
spinal galanin with overall reduction of thermal hyperal-
gesia and mechanical allodynia. In a different note, Liu
et al. [68] in 2004 engineered a replication-incompetent
herpes simplex virus (HSV) vector expressing one iso-
form of the human glutamic acid decarboxylase (GAD)
and transfected rats with T13 spinal cord hemisection
via subcutaneous inoculation. The recipient rats exhib-
ited less neuropathic pain presumably due to increased
levels of GABA at the dorsal root ganglion (DRG). Lee
et al. [69] conducted a similar study but in addition,
explored the effects of another strain of non-replicating
HSV vector expressing proenkephalin. He found the
reduction in pain behaviour was less significant with the
proenkephalin-expressing vectors. In 2009, Miyazato et
al. [70] injected GAD expressing HSV-vectors into the
bladder walls of rats with SCI and found alleviation of
detrusor overactivity, supporting the hypothesis that the
GAD gene therapy enhanced GABA-mediated suppres-
sion of neuropathic signals. Encouraged by these experi-
mental findings, Wolfe et al. [71] embarked upon a
Phase I single-centre, open-label, dose-escalating trial
using a clinical grade of replication-incompetent HSV
virus expressing human preproenkephalin gene (called
NP2). Patients with intractable pain due to malignancy
below the angle of the jaw were enrolled and NP2 virus
was administered by innoculation. At time of writing,
the trial is still in progress and results are pending.
Using stem cells
Use of stem cells has phenomenally advanced regenera-
tive medicine and equally has aroused enormous med-
ico-legal controversies, especially regarding the use of
embryonic stem cells derived from human beings. In the
last decade, mesenchymal stem cells (MSC) have
remained a major focus of stem cells research. MSC are
found in the adult bone marrow with a mesodermal ori-
gin and are capable of differentiating into cells that con-
stitute the blood, adipose tissue, connective tissues, the
vascular and urogenital system [72]. In vitro, MSC can
be expanded easily from a small amount of bone mar-
row aspirate with stable phenotype and genotype, and
are easily transported in various methods and formula-
tions from the bench to the bedside [73]. Moreover,
MSC migrate to sites of tissue injury with extraordinary
immunosuppressive properties and their ability to differ-
entiate into neurons and astrocytes have been documen-
ted both in vitro and in vivo [74]. In addition, MSC can
enhance synaptic transmission and promote neuronal
network in mice model of neurodegeneration [75], mak-
ing MSC a prime candidate for nervous system repair.
In the context of neuropathic pain, direct injection of
human mesenchymal stem cells (hMSC) into the cere-
bral ventricle of mice with spinal nerve injury (SNI)
reduced formation of neuropathic pain [76]. So far,
three clinical studies have been published regarding the
use of bone marrow MSC for spinal cord injury. In
2006, basing on their previous findings that human
MSC derived from adult bone marrow can trans-differ-
entiate into neural stem cells when co-cultured with
auto-reactive T-lymphocytes [77], Moviglia et al. [45]
(Table 1) reported clinical extension of spinal cord func-
tion in two patients when given these MSC pre-primed
with anti-T cells autoserum and noted no apparent
adverse effects. In 2009, Kishk et al. [46] (Table 1) con-
ducted an open label case-control study with 64 patients
who had SCI within an average of 3.6 years. 44 patients
consented to monthly autologous MSC transplant for 6
months, which was given intrathecally. The 20 patients
who refused therapy served as controls. All patients
were evaluated for adverse effects and functional
improvements 12 months after the therapy. Results were
disappointing as no significant between-group improve-
ments as per clinical measures were detectable, with
additional adverse effects of spasticity in 9.3% and neu-
ropathic pain in 55.8% of subjects who received therapy.
In 2010, Ichim et al. [47](Table 1) gave three cycles of
combined allogeneic MSC and expanded umbilical cord
blood CD34 cells intrathecally over a period of 14
months to a patient with incomplete spinal cord injury.
They reported significant reduction of neuropathic pain
from an intermittent 10/10 to weekly 3/10 basing on the
visual analogue scale (VAS). Other improvements in
terms of muscle, bowel and sexual function were also
noted without any adverse effects.
Using bone marrow and bone marrow stem cell
transplant
Instead of using the specific mesenchymal portion of
bone marrow, several clinical studies have employed
autologous whole bone marrow transplant or its stem
cell abstract for treating spinal cord injury. In 2006, a
case study from Czech republic [48](Table 1) recruited
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pulated autologous bone marrow transplant intra-arte-
rially 10 to 467 days post-injury. Results showed general
level of safety with improvement in terms of sensory
and motor functions mostly amongst the acutely injured
group, and the authors cautioned that the observed ben-
efits might be confounded by the natural recovery pro-
cesses. Yoon et al. [49](Table 1) conducted a Phase I/II
open label non-randomised study in 2007 with 35
patients diagnosed with complete spinal cord injury.
They received autologous bone marrow cell transplant
together with granulocyte macrophage-colony stimulat-
ing factor (GM-CSF) within 8 weeks of injury directly at
t h es i t eo fs p i n a ll e s i o n .N oa d v e r s ee f f e c t so ft u m o u r ,
cysts or neuropathic pain was observed up to 10.4
months after injury, with improvement of clinical mea-
sures up to 30.4%. In 2008, Geffner et al. [50](Table 1)
in Ecuador also described improvement in clinical mea-
sures with relatively minor adverse effects when bone
marrow stem cells were given to an uncontrolled series
of 52 patients with SCI via multiple routes of adminis-
tration(spinal cord injection, spinal canal injection and
intravenous). By far the largest Phase I/II study was con-
ducted in 2009 by Kumar et al. [51](Table 1) in India.
297 patients who had SCI were enrolled and they
received a single treatment of unmanipulated autologous
mononuclear bone marrow cells transplantation via
lumbar puncture. They were then followed for up to a
mean of 20.4 months and approximately 1/3 of patients
showed some form of sensory or motor improvements,
which were dependent on the absolute number of CD34
+ cells transplanted. The group concluded that such
treatment was relatively safe without any serious adverse
effects. However, not all SCI clinical studies using bone
marrow transplants yielded convincing benefits. A pilot
conducted by Pal et al. [52](Table 1) in 2009 recruited
thirty patients with complete SCI within 6 months of
injury. They received a single treatment of autologous
ex-vivo expanded bone marrow transplant via lumbar
puncture and showed no harmful effects but benefits
were only apparent for patients with less than 6 months
of injury. However, as most patients with acute SCI will
recover spontaneously within 3 to 18 months regardless,
it is necessary to have a large enough sample size to
demonstrate validity and statistical significance for true
benefits of any therapeutic intervention [78]. Hence, Pal
et al. rightly questioned if their observed improvements
were genuinely due to treatment itself.
Other cell-related strategies for SCI with
implications to neuropathic pain
Olfactory ensheathing cells (OECs)
The olfactory mucosa is a fascinating anatomical area
with incessant regenerative potential. It contains both
multipotent progenitor cells and olfactory ensheathing
cells (OECs), the former capable of differentiating into
both neural and non-neural cells [79], and the latter
capable of promoting axonal remyelination and regen-
eration after injury. It is of interest to note that OECs,
though normally associated with axons of the first cra-
nial nerve, do not myelinate the olfactory nerve per se.
They only assume a myelinating prototype when trans-
planted to the vicinity of axons of larger diameter [80].
Research findings in the last decade have suggested
that transplanting OECs into damaged spinal cord pro-
motes axonal regeneration and remyelination, facilitat-
ing overall functional recovery of the spinal cord
[81-83]. However, this view has been challenged when
OEC graft transplanted to rats with rhizotomy failed to
enable axonal regeneration beyond the dorsal root
entry zone [84-86]. Moreover, controversy has been
intense as to whether these regeneration-capable olfac-
tory cells are OECs or in fact, Schwann cells. OECs
resemble Schwann cells so closely in terms of bio-
chemistry, microscopic morphology and molecular
transcription that it is often impossible to distinguish
between the two [80]. Basing on their earlier findings
with genomic studies that calponin is a definitive phe-
notypic marker for OECs which is not shared by
Schwann cells [87], Kawaja’s group found that primary
cultures of olfactory mucosa and bulb often contained
a mixture of calponin-positive OECs and calponin-
negative Schwann cells [88]. In other words, what is
normally thought as “OECs culture” will be invariably
contaminated by Schwann cells. Hence, the concept of
OECs remyelinating damaged axons without the influ-
ence of Schwann cells might need revision. In a recent
authoritative review, Kawaja et al. [89] exhaustively cri-
tiqued the technical strategies of obtaining and cultur-
ing OECs from olfactory mucosa or olfactory bulb of
various animal species and humans, the different bio-
markers used for identifying OECs, and offered a state-
of-the-art opinion on the controversy of Schwann cell
contamination amongst OECs. Thus said, experimental
data have shed enough light for clinical trialing of
OECs in patients with SCI. In 2004, Mackay-Sim et al.
conducted a Phase I/IIa study using autologous trans-
plantation of OECs in six patients with thoracic para-
plegia with follow-up at one year [53] and three years
[54](Table 1), and the group concluded that such pro-
cedure seemed to be safe with no consequences of
iatrogenic neuropathic pain or tumour formation.
However, only one out of the six subjects showed
improvement in sensory function over three segments
of the thorax. In 2006, Huang et al. [55](Table 1) fol-
lowed 16 patients with SCI who received heterologous
OECs transplants from aborted foetuses and they
found no major adverse effects or pathology within 38
Leung Journal of Translational Medicine 2012, 10:37
http://www.translational-medicine.com/content/10/1/37
Page 6 of 14months of the procedure. There was, however, no
mention of functional improvement or clinical symp-
toms. More favourable outcomes were reported by
Lima et al. [56](Table 1) who conducted a pilot study
with seven patients having olfactory mucosal autografts
(OMA) directly transplanted into their spinal cord
lesions. They exhibited good improvements in bladder
sensation, anal sphincter function and overall paraple-
gic scores according to the American Spinal Injury
Association (ASIA). There was also corresponding
remyelination of the lesional sites as documented by
spinal MRI scan. The same group hence proceeded to
a prospective study in 2010 [57] (Table 1) using the
same protocol with a larger sample size of 20 patients.
They confirmed similar clinical benefits and radiologi-
cal improvements as with their initial pilot study.
However, such promising findings were not replicated
in the five patients recruited by Chhabra et al. [58]
(Table 1), for which the authors attributed to the pro-
cedures involved. In addition, adverse effects of syrinx
formation in one subject and extension of myelomala-
cia in four subjects were reported.
Schwann cells
Discovered by Theodore Schwann (1810-1882),
Schwann cells are a major component of the peripheral
nervous system derived embryonically from the neural
crest cells. Schwann cells grow in juxtaposition to axons
and also myelinate them. Following axonal injury,
Schwann cells de-differentiate into the non-myelinating
phenotype and proliferate, secreting an array of growth
modulators like collagen IV, laminin and fibronectin in
the surrounding domain [90]. In experimental models of
SCI, Schwann cells were found to be present in the
regenerated areas [91-93], which helped to regenerate
the axons with various neurotrophic factors like nerve
growth factor (NGF)[94], brain-derived neurotrophic
factor (BDNF)[95], Neutrotrophin-3 (NT-3)[96], glial
derived growth factor (GDNF)[97] and pleiotrophin
(PTN, HB-GAM) [98]. In particular, Schwann cells seem
to exhibit distinct motor or sensory phenotypes as per
immunoreactivity towards PTN which direct regenerat-
ing axons towards the specific phenotypes [99]. Recent
improvement in cell harvesting and proliferation techni-
ques have enabled human Schwann cells to be obtained
in a sufficiently large and purified amount for reparative
purpose of spinal cord injury. Saberi et al. [59](Table 1)
studied the effects of human autologous Schwann cell
transplant purified from autologous sural nerve culture
in four patients with mid-throacic spinal cord injury.
They reported lack of adverse effects overall with
improvement in sensory and motor functions in only
one patient, and MRI scanning failed to show any corre-
sponding changes in white matter.
Specific anti-cytokine treatment: the rise and fall of TNF-a
As mentioned above, SCI leads to a myriad of neuroin-
flammatory mediators which contribute to the pathogen-
esis of neuropathic pain. Amongst them, tumor necrosis
factor-alpha (TNF-a) is one of the most extensively stu-
died which can be detected promptly after experimental
models of spinal cord injury [100]. First discovered in
1891 from a mixed extract of Streptococcus pyogenes and
Serratia marcescens bacteria [101] and later characterised
with tumor-regression activity [102], TNF-a belongs to a
superfamily of ligand/receptor proteins called the tumor
necrosis factor/tumor necrosis factor receptor superfamily
proteins (TNF/TNFR SFP). TNF-a possess a trimeric sym-
metry with a structural motif called the TNF homology
domain (THD), which is shared with all other members of
the TNF proteins. This THD binds to the cysteine-rich
domains (CRDs) of the TNF receptors (TNFRs), and varia-
tions of these CRDs lead to heterogeneity of the TNFRs
[103]. TNFRs are either constitutively expressed (TNFR1,
p55-R) or inducible (TNFR2, p75-R) [104]. The inducible
TNFR2 forms the basic architecture of etanercept, an FDA
approved drug for treating severe rheumatoid arthritis and
plaque psoriasis. In the context of neuropathic pain, using
the CCI model in rats, TNF-a is detectable at the injury
site in a temporal up-regulation [105-107], located mainly
in both the macrophages [108] and the Schwann cells
[109,110]. Similarly, there is local up-regulation of both
TNFR1 and TNFR2 as the injured neurons undergo Wal-
lerian degeneration, albeit at a differential rate [111].
Further upstream, there is enhanced TNF immunoreactiv-
ity in the dorsal root ganglion (DRG) of both the injured
and spared ipsilateral adjacent afferents [112], plus the
contralateral uninjured counterparts [113], which can only
be partly explained by retrograde axonal transport [114].
There is also a corresponding up-regulation of TNFR1
and TNFR2 in both the nerve and the DRG [115], with a
temporal pattern of an increase of TNF mRNA expression,
first in the sciatic nerve, and then in the DRG [116].
Finally, glial TNF-a is thought to play a role in mediating
the central mechanisms of neuropathic pain. Using classic
CCI models in rats, increased levels of TNF-a are found
in the hippocampus [117,118], locus coeruleus [118,119]
and the red nucleus [120] of the brain. Albeit the ubiquity
of TNF-a following experimental models of spinal cord
injury, randomised controlled clinical trials of infliximab
(antibody to TNF-a) and etanercept (recombinant
TNFR2) have not demonstrated benefits for patients with
discogenic sciatica [121-124], which thwarted further
research of anti-TNF-a treatment for other types of neu-
ropathic pain. In comparison, clinical trial regarding the
use of anti-TNF-a for spinal cord injury or related neuro-
pathic pain is lacking, with only one case study reporting
significant motor improvement and reduction of inflam-
mation at the injured cord area of a patient who
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spondylitis shortly before a T7-cord transection accident
[60](Table 1).
Disinhibiting axonal regrowth: no go to nogo
The spinal cord attempts to self-repair after any injury,
which often ends in failure due to a combination of glial
scar and growth inhibitors associated with myelin. Glial
scar is formed by a congregation of meningeal fibro-
blasts, activated astrocytes, microglia and oligodendro-
cytes which on one hand, physically barricade the
regenerating axons and on the other hand, secret an
array of chondroitin sulphate proteoglycans (CSPGs)
which chemically deter neurite outgrowths [125]. Pre-
sumably from the initial surge of Schwann cell activity
to repair and myelinate the damaged axons [126], mye-
lin-associated growth inhibitors like Nogo-A, myelin-
associated glycoprotein (MAG) and oligodendrocyte-
myelin glycoprotein (OMG)[127] rapidly dominate the
area and prevents further axonal growth and regenera-
tion. Experiments with animal transgenic mutants defi-
cient in these myelin-associated inhibitors have
demonstrated better axonal growth and locomotory
functions after spinal cord injury [128,129], which fos-
ters the idea of antagonising these myelin-associated
inhibitors to enable axonal re-growth and hence spinal
cord regeneration. In 2010, a Phase I clinical trial of
anti-Nogo-A in patients with acute spinal cord injury
has been embarked by Zorner et al. [61](Table 1).
Against cell cycle activation
From animal experiments, there is evidence that cell
cycling is activated during SCI which leads to neuronal
cell death [130,131], oligodendrocytes loss [131], inflam-
mation [132,133], tissue scaring [134] and astrogliosis
[132]. Increased cell cycling is seen by enhanced pro-
duction of cycle proteins like cyclins [135], cyclin-acti-
vated kinases [136,137] and inhibitors of cyclin-
dependent kinases [138]. It has been shown that cell
cycle inhibitors are capable of reducing axonal damage
and lead to functional recovery [131,132,134] in animal
models of spinal cord injury. Other inhibitory molecules
that affect axonal regeneration in spinal cord injury
include the Wnts molecules [139], semophorin 3
(SEMA3)[139] and the RhoA signalling pathway [140].
Despite the state of accumulated knowledge, no clinical
trials have been approved or in progress to test the effi-
cacy of these cell cycle inhibitors on patients with SCI.
Neurotrophins: a friend or foe for spinal cord injury?
Neurotrophins refer to the class of growth factors in the
CNS that promote growth, maintenance and survival of
neurons and synapses. They comprise of NGF, BDNF,
NT-3 and NT-4/5 [40]. In rats and primates, the levels
of neurotrophins peak initially in the embryonic stage
where neurons and synapses are produced in abundance
for matching and paring, after which the levels generally
decline when inappropriate neurons and synapses are
eliminated towards the adult neuronal profile [141,142].
Following acute hemisection of the spinal cord in Rhe-
sus monkeys, the levels of NGF, BDNF and NT-3
decreased sharply from day 3 to Day 7 and increased
persistently up to Day 30 [143], consistent with the
attempt of intrinsic neuronal repair. Coupled with other
experimental data showing that exogenously applied
neurotrophins promote regeneration of various neuronal
populations after various periods of spinal cord injury
[144-146] even up to a period of 15 months [147], neu-
rotrophins would be a promising therapy for spinal cord
repair in humans. However, caution is needed in several
areas when translating the positive findings from pre-
clinical studies in rodents to clinical consideration: (i)
there are species-specific differences in neuro-plasticity
which necessitate regeneration of the corticospinal tracts
in primates when restoring sensori-motor activities dur-
i n gs p i n a lc o r di n j u r y ,b u ts u c hp r e - r e q u i s i t ei sn o t
shared by rodents [148]; (ii) the role and specificity of
neurotrophins involved in promoting axonal regenera-
tion and preventing corticospinal neuronal atrophy in
spinal cord repair maybe different [149]; (iii) neurotro-
phins as therapy for CNS regeneration can lead to unde-
sirable effects, e.g., exogenous administration of BDNF
in experimental models can contribute to spinal nerve
injury-induced neuropathic pain by activation of micro-
glia [150] and astrocytes [151], whilst intra-cerebroven-
tricular infusion of NGF leads to weight loss and
neuropathic pain in one clinical pilot [152].
Hurdles of cellular therapies in human
Despite the promising prospect from various modalities
as described above, there are a few hurdles to be sur-
mounted before cellular therapies can be channelled
towards large-scale clinical trials and eventual bedside
use. For convenience of discussion, we shall choose
stem cell therapy to illustrate such challenges.
Cells generation and homogeneity
There is as yet a standardised and efficient protocol to
produce a specific type of stem cells in quantities large
enough for clinical therapy. The combined protocol of
feeder cells, growth factors and genetic modulation has
been the traditional method for expanding the colonies
of hESC [153] with average yield of < 20% [140], which
in defined conditions can be enhanced to 95% with
small molecule induction using retinoic acid [154]. In
reality, it remains a technical challenge to conform stem
cell differentiation to a particular phenotype, although a
novel approach with nanofiber-scaffold drug release
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in committing MSC towards a neural differentiation
[155]. Genome wide analysis has been used to monitor
the quality and differentiation of hESC lines regarding
the dynamics of “stemness genes”[156] and possible fee-
der contaminations [157]. It would be beneficial if tran-
scriptomic and proteomic datasets are readily available
for neuroscientists studying hECS to a degree as for
studying OEC [158] and MSC [159].
Cell dosing and delivery
Dosing of stem cells in terms of upper limit and fre-
quency of administration remains controversial. Intui-
tively one would expect an incremental response with
dose escalations but available data is limited. Recent
s t u d yb yU s v a l det al. [160] demonstrated an optimum
dosing regimen for intra-parenchymal injection of
human spinal stem cells into minipigs spinal cord for
the best neuronal repopulation. Other studies have sug-
gested that intra-thecal and intra-venous delivery of
stem cells were less efficacious than direct injection into
the spinal cord tissue, albeit the danger of further
damage to the lesion [161,162]. Vaquero et al. [163] also
showed that intra-lesional injection of stem cells in rats
with SCI produced better outcome than intravenous
administration. Thus said, it is still a challenge to target
the stem cells within cellular precision. Recent study by
Wu et al. [164] proposed the use of fibrin glue as a
vehicle for delivering MSC to injured neural tissues.
Cell tracking and outcome measure
It would be ideal to track the stem cells after being
administered to determine their distribution, location,
quantity, viability and final differentiation for both
research and clinical purposes. Non-invasive strategies
include (i) direct labelling of target cells with paramag-
netic contrast agents and tracking them with functional
MRI, either using gadolinium [165,166], supermagnetic
iron oxide particles [167,168], or
19F isotope [169]; (ii)
direct labelling with traditional fluorochromes like
PKH26 [170] or quantum dots using cadmium nano-
crystals [171,172]; (iii) internal labelling using trans-
fected enhanced green fluorescence protein (eGFP) and
firefly luciferase (fLuc) reporter genes either via the bio-
luminescence mechanism [173,174]. Each of these cell
tracking methods suffer from drawbacks: paramagnetic
contrast uptake can be limited and MRI signals maybe
weak (except using the supermagnetic iron oxide parti-
cles); traditional fluorochromes are prone to bleaching
whilst cadmium in quantum dots crystals are toxic to
cells; finally, bioluminescence imaging maybe be limited
by the low tissue penetrance [175].
Conclusions and future directions
Spinal cord injury is a devastating condition in humans
leading to significant disability with immense loss of
quality of life and economic output. At time of writing,
there is no satisfactory clinical cure and overall prog-
nosis is poor. In the last two decades, experimental data
using cellular or cell-related therapies have opened up
exciting therapeutic possibilities. Various clinical studies
using cellular therapies for spinal cord injury have been
discussed above and are summarised in Table 1 for ease
of reference. For spinal cord regeneration, stem cell
transplantation still holds the best future and amongst
them, hESC [176] and OEC [177] are currently the
prime candidates. However, with the abrupt withdrawal
of Geron from the GRNOPC1 Phase I clinical trial, the
actual immaturity of hESC research in spinal cord inju-
ries and its vulnerability to financial considerations is
well illustrated [178]. As regards to combating neuro-
pathic pain related to spinal cord injury, cellular or cell-
related therapies are rapidly gathering momentum
which aim to achieve analgesia from different perspec-
tives: preventing neuronal damage due to inflammation,
cell cycling or dysfunctional regeneration; installing bio-
logical mini-pumps using adrenal medullary chromaffin
tissues, engineered cell lines or astrocytes and finally,
regulating the internal milieu using transplant of bone
marrow of bone marrow mesenchymal stem cells.
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